Hesperidin and Diosmin Effect on Metabolic Syndrome

Not Applicable

Completed

• Conditions: Metabolic Syndrome and Diabetic Neuropathy

• Registration Number: NCT05243238
• Lead Sponsor: Beni-Suef University

Brief Summary

The components of metabolic syndrome (MetS), particularly obesity and dyslipidemia, are linked to peripheral neuropathy (PN) among patients with diabetes or even without diabetes. Several studies revealed that complementary and herbal medicine could provide a potential for PN management and MetS components. Thus, designing clinical trials with interventions combinations to achieve a considerable improvement is highly recommended. Hesperidin and diosmin, citrus-derived flavonoids, have been reported to possess anti-hyperlipidemic, anti-inflammatory, analgesic, antioxidant, antidiabetic, and anti-hypertensive effect with high tolerability and safety profile

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-01
• Primary Completion: 2020-11-30
• Study Completion: 2021-11-12
• Status Verified: 2022-02
• Study First Submitted: 2022-02-03
• Study First Submitted QC: 2022-02-14
• Last Update Submitted: 2022-02-14
• Study First Posted: 2022-02-17
• Last Update Posted: 2022-02-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 129

Inclusion Criteria

Type 2 diabetes adult patients who meet metabolic syndrome criteria and with diabetic neuropathy

Exclusion Criteria

patients without any parameter of inclusion criteria

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
metabolic syndrome components	12 weeks	TGs, mg/dl
MNSI score for neuropathy	12 weeks	neuropathy improvement if MNSI score decreased

Trial Locations

Locations (1)

University; 🇪🇬 Fayoum, Egypt